Global Medical Alpha Radionuclide Market Growth 2024-2030

Global Medical Alpha Radionuclide Market Growth 2024-2030

Targeted alpha-particle therapy (or TAT) is an in-development method of targeted radionuclide therapy of various cancers. It employs radioactive substances which undergo alpha decay to treat diseased tissue at close proximity. It has the potential to provide highly targeted treatment, especially to microscopic tumour cells. Targets include leukemias, lymphomas, gliomas, melanoma, and peritoneal carcinomatosis. As in diagnostic nuclear medicine, appropriate radionuclides can be chemically bound to a targeting biomolecule which carries the combined radiopharmaceutical to a specific treatment point.

The global Medical Alpha Radionuclide market size is projected to grow from US$ 3467 million in 2024 to US$ 8080 million in 2030; it is expected to grow at a CAGR of 15.1% from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “Medical Alpha Radionuclide Industry Forecast” looks at past sales and reviews total world Medical Alpha Radionuclide sales in 2023, providing a comprehensive analysis by region and market sector of projected Medical Alpha Radionuclide sales for 2024 through 2030. With Medical Alpha Radionuclide sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Medical Alpha Radionuclide industry.

This Insight Report provides a comprehensive analysis of the global Medical Alpha Radionuclide landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Medical Alpha Radionuclide portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Medical Alpha Radionuclide market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Medical Alpha Radionuclide and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Medical Alpha Radionuclide.

United States market for Medical Alpha Radionuclide is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Medical Alpha Radionuclide is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Medical Alpha Radionuclide is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Medical Alpha Radionuclide players cover ORNL, Tri-Lab, SSC RF-IPPE, JRC Karlsruhe, TerraPower, etc. In terms of revenue, the global two largest companies occupied for a share nearly

% in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Medical Alpha Radionuclide market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Actinium-225
Astatine-211
Lead-212
Bismuth-213
Others

Segmentation by Application:
Immunotherapy
Peritoneal Carcinomas
Bone Metastases
Leukaemia
Melanomas
Solid Tumours

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
ORNL
Tri-Lab
SSC RF-IPPE
JRC Karlsruhe
TerraPower
TRIUMF
Eckert&Ziegler
Ionetix
Orano Med
National Nuclear Laboratory
NorthStar

Key Questions Addressed in this Report

What is the 10-year outlook for the global Medical Alpha Radionuclide market?

What factors are driving Medical Alpha Radionuclide market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Medical Alpha Radionuclide market opportunities vary by end market size?

How does Medical Alpha Radionuclide break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.